OSE Immunotherapeutics (PAR: OSE)

Currency in EUR

Last close As at 25/03/2023


−0.05 (−0.97%)

Market capitalisation


OSE Immunotherapeutics is based in Nantes and Paris in France and is listed on the Euronext Paris exchange. It is developing immunotherapies for the treatment of solid tumours and autoimmune diseases and has established several partnerships with large pharma companies.

OSE has products in development for both immunological diseases and various cancer indications. As a result, the R&D pipeline is diversified and the outlook does not depend on developments in any specific subsector.




Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Alexis Peyroles


  • Dominique Costantini


Balance Sheet

Forecast net debt (€m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual (4.8) (22.6) (38.8)
Relative (2.5) (29.0) (42.0)
52 week high/low €9.5/€4.8


OSE Immunotherapeutics has announced that the data from its earlier Phase I study for OSE-127/S95011, initially released in 2019, has been published in the Journal of Immunology. The study, involving 63 healthy volunteers, was a first-in-human, randomised, double-blind, placebo-controlled trial that demonstrated a promising safety and tolerability profile for OSE-127. This candidate is a monoclonal antibody therapy being assessed as a treatment for primary Sjögren’s syndrome (pSS) and ulcerative colitis (UC) in two ongoing Phase IIa studies (NCT04605978 and NCT04882007). Patient enrolment for the pSS trial was completed in Q422, with updates expected in H123; readouts for UC are expected in FY23. While we caution read-across between studies, we believe the high target occupancy observed in the Phase I study, along with a favourable safety profile, support the ongoing clinical programmes involving OSE-127.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2020A 10.4 (18.1) (18.5) (101.83) N/A N/A
2021A 26.3 (13.6) (16.5) (89.03) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free